CN110461318A - 用chs-131治疗多发性硬化 - Google Patents

用chs-131治疗多发性硬化 Download PDF

Info

Publication number
CN110461318A
CN110461318A CN201780069826.5A CN201780069826A CN110461318A CN 110461318 A CN110461318 A CN 110461318A CN 201780069826 A CN201780069826 A CN 201780069826A CN 110461318 A CN110461318 A CN 110461318A
Authority
CN
China
Prior art keywords
effective amount
therapeutically effective
multiple sclerosis
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201780069826.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·芬克
R·兹瓦迪诺夫
H·唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellin Therapeutic Co Ltd
Original Assignee
Intellin Therapeutic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellin Therapeutic Co Ltd filed Critical Intellin Therapeutic Co Ltd
Publication of CN110461318A publication Critical patent/CN110461318A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780069826.5A 2016-09-13 2017-09-13 用chs-131治疗多发性硬化 Withdrawn CN110461318A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662394046P 2016-09-13 2016-09-13
US62/394,046 2016-09-13
US201662436356P 2016-12-19 2016-12-19
US62/436,356 2016-12-19
US201762460868P 2017-02-19 2017-02-19
US62/460,868 2017-02-19
US201762491071P 2017-04-27 2017-04-27
US62/491,071 2017-04-27
PCT/US2017/051414 WO2018053040A1 (en) 2016-09-13 2017-09-13 Treatment of multiple sclerosis with chs-131

Publications (1)

Publication Number Publication Date
CN110461318A true CN110461318A (zh) 2019-11-15

Family

ID=61619253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780069826.5A Withdrawn CN110461318A (zh) 2016-09-13 2017-09-13 用chs-131治疗多发性硬化

Country Status (12)

Country Link
US (1) US20190224186A1 (https=)
EP (1) EP3512512A4 (https=)
JP (1) JP2019531286A (https=)
KR (1) KR20190064583A (https=)
CN (1) CN110461318A (https=)
AU (1) AU2017326261A1 (https=)
BR (1) BR112019004791A2 (https=)
CA (1) CA3036694A1 (https=)
IL (1) IL265259A (https=)
MX (1) MX2019002901A (https=)
SG (1) SG10202102198RA (https=)
WO (1) WO2018053040A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228622A (zh) * 2013-01-30 2016-01-06 因特克林医疗有限公司 用于治疗多发性硬化的PPARγ激动剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
BR112015007782A2 (pt) * 2012-10-12 2017-07-04 Teva Pharma laquinimod para reduzir danos talâmicos na esclerose múltipla

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228622A (zh) * 2013-01-30 2016-01-06 因特克林医疗有限公司 用于治疗多发性硬化的PPARγ激动剂
JP2016506956A (ja) * 2013-01-30 2016-03-07 インテクリン・セラピユーテイクス・インコーポレイテツド 多発性硬化症を治療するためのＰＰＡＲγアゴニスト

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATRICIA G: "Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis", 《 COHERUS BIOSCIENCES INC 》 *

Also Published As

Publication number Publication date
JP2019531286A (ja) 2019-10-31
BR112019004791A2 (pt) 2019-06-04
CA3036694A1 (en) 2018-03-22
EP3512512A4 (en) 2020-06-03
WO2018053040A1 (en) 2018-03-22
SG10202102198RA (en) 2021-04-29
IL265259A (en) 2019-05-30
US20190224186A1 (en) 2019-07-25
MX2019002901A (es) 2019-09-26
EP3512512A1 (en) 2019-07-24
KR20190064583A (ko) 2019-06-10
AU2017326261A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
EP3206682B1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
CN110461318A (zh) 用chs-131治疗多发性硬化
JP2002537332A (ja) 内臓痛を予防及び治療するためのガバペンチン誘導体
JPWO2000009127A1 (ja) 多発性硬化症治療薬
JP6466540B2 (ja) 多発性硬化症を治療するためのＰＰＡＲγアゴニスト
US12318380B2 (en) Treatment of demyelinating diseases
RS64481B1 (sr) Lečenje alchajmerove bolesti kod posebne populacije pacijenata
EP2882495A1 (en) Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders
TW201125562A (en) Sustained release fampridine treatment in patients with multiple sclerosis
US20180338992A1 (en) Il-34 antisense oligonucleotides and methods of using same
WO2014028397A2 (en) Laquinimod for treatment of gaba mediated disorders
JP5753843B2 (ja) ｐ４０依存性疾患の治療におけるベンジダミンの使用
US20210023032A1 (en) Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
JP2022515615A (ja) 慢性炎症性腸疾患の治療のためのｐａｒ－１アンタゴニストの使用
US20190099387A1 (en) Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
CN111617255B (zh) 用于治疗中枢神经系统紊乱的组合疗法
Egan et al. HIGHER TROUGH GOLIMUMAB LEVELS ARE ASSOCIATED WITH EARLY CLINICAL AND BIOCHEMICAL RESPONSE; EARLY RESULTS OF THE GOAL-ARC STUDY
WO2025248089A1 (en) Haloquinolines for treating immune-mediated inflammatory diseases
Kumar et al. Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: a focused review for orphan drug (Tofersen)
US20240299410A1 (en) Methods of treating familial amyotrophic lateral sclerosis by oral administration of fasudil
EP4699605A1 (en) Use of novel compound for treating intractable diseases
JP2022542145A (ja) 神経変性障害の処置のための銅複合体
HK1221913B (zh) Par-1拮抗剂用於预防和/或治疗骨盆-会阴功能病状的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20191115